Skip to main content

Thermo Completes Fermentas Acquisition

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has completed its $260 million acquisition of Fermentas International.

Fermentas sells reagents for nucleic acid and protein purification, restriction and modifying enzymes, molecular weight markers, and other life science research and diagnostic tools. It also offers various products for polymerase chain reaction, reverse transcription PCR, and quantitative PCR.

The firm will be integrated into Thermo Fisher's Analytical Technologies segment.

Based in Burlington, Ontario, with principal operations in Vilnius, Lithuania, Fermentas employs about 500. In 2009, it posted revenues of about C$57 million ($54 million).

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.